AbCellera Biologics Inc. (NASDAQ: ABCL) Stock News & Analysis
AbCellera Biologics Inc. (NASDAQ: ABCL) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 1 article on ABCL since Wednesday, June 17, 2026, most recently "AbCellera, Jazz Pharmaceuticals Sign $848M T-Cell Antibody Collaboration (NASDAQ: ABCL)" on Wednesday, June 17, 2026. Coverage to date spans Health Care, tracking ABCL's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
ABCL Coverage -- 1 Article
AbCellera, Jazz Pharmaceuticals Sign $848M T-Cell Antibody Collaboration (NASDAQ: ABCL)
Jazz Pharmaceuticals is paying AbCellera $56M upfront, with up to $792M more per program, to co-develop next-gen cancer-fighting antibodies.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.